Laddar...
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved...
Sparad:
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2010
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2895774/ https://ncbi.nlm.nih.gov/pubmed/20616957 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|